Q4 2025 SOPHiA GENETICS SA Earnings Call Transcript
Key Points
- Sophia Genetics SA (SOPH) achieved a 22% revenue growth in Q4 2025, reaccelerating the business toward historical levels.
- The company signed a record 124 new customers in 2025, significantly outperforming internal booking targets.
- Sophia Genetics SA (SOPH) expanded its adjusted gross margin by 140 basis points to 74.2% in 2025.
- The company has a Net Promoter Score of 67 and a customer satisfaction score over 97%, indicating high customer satisfaction.
- Sophia Genetics SA (SOPH) announced a strategic collaboration with MD Anderson to develop new AI-driven tests, reflecting expanding capabilities.
- Sophia Genetics SA (SOPH) faced adverse foreign exchange movements, impacting reported operating expenses due to the strengthening of the Swiss franc.
- The company incurred $1.8 million in legal expenses due to patent infringement claims by Guardant Health.
- Operating loss for Q4 2025 was $18.5 million, compared to $17.4 million in the prior year period.
- Sophia Genetics SA (SOPH) reported an EBITDA loss of $61.4 million for the full year 2025, compared to $58 million in 2024.
- The company experienced a slight decrease in adjusted gross margin by 30 basis points year-over-year in Q4 2025.
Good morning. My name is Angeline, and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS fourth quarter and full year 2025 earnings conference call. (Operator Instructions) I will now turn the conference call over to Kellen Sanger, SOPHiA GENETICS VP of Strategy. You may begin.
Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS fourth quarter and full year 2025 earnings conference call.
Joining me today to discuss the results are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer; Ross Muken, our Company President; and George Cardoza, our Chief Financial Officer.
I'd like to remind you that management will make statements during this call that are forward-looking statements within the meanings of federal securities laws.
These statements involve material risks and uncertainties that could cause actual results or events
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
